Successful use of recombinant factor VIIa for emergency fasciotomy in a patient with hemophilia A and high-titer inhibitor unresponsive to factor VIII inhibitor bypassing activity

American Journal of Hematology

Volumn 79, Issue 1, 2005, Pages 58-60

  Watts, Raymond G ^a  

^a University of Alabama at Birmingham   (United States)

Author keywords

Compartment syndrome; Factor VIIa; FEIBA; Hemophilia A; Hemorrhage; Inhibitor

Indexed keywords

ACTIVATED PROTHROMBIN COMPLEX; BLOOD CLOTTING FACTOR 8 INHIBITOR; BLOOD CLOTTING FACTOR 9; RECOMBINANT BLOOD CLOTTING FACTOR 7A;

ARTICLE; BLEEDING; CASE REPORT; COMPARTMENT SYNDROME; DISEASE COURSE; EMERGENCY SURGERY; EMERGENCY TREATMENT; FASCIOTOMY; HEMOPHILIA A; HEMOSTASIS; HUMAN; MALE; MEDICAL DECISION MAKING; PRIORITY JOURNAL; SCHOOL CHILD; TREATMENT OUTCOME;

AUTOANTIBODIES; CHILD; EMERGENCIES; FACTOR VIIA; FACTOR VIII; FASCIA; HEMOPHILIA A; HUMANS; MALE; RECOMBINANT PROTEINS;

EID: 18044380093     PISSN: 03618609     EISSN: None     Source Type: Journal    
DOI: 10.1002/ajh.20314     Document Type: Article

References (21)

1. Kulkarni R, Aledort LM, Bertrop E, et al. Therapeutic choices for patients with hemophilia and high titer inhibitors. Am J Hematol 2001;67:240-246.
2. Tarantino M, Aledort L. On the treatment of hemorrhage in patients with hemophilia and associated inhibitors. Transfusion 2001;41:1628.
3. Aledort LM. Unsolved problems in hemophilia. Hemophilia 1998;4:341-345.
4. Brackmann HH, Lenk H, Scharrer G, Auerswald G, Kreuz W. German recommendations for immune tolerance therapy in type A haemophiliacs with antibodies. Haemophilia 1999;5:203-206.
5. Hilgartner MW, Knatterud GL. The use of factor eight inhibitor by-passing activity (FEIBA immuno) product for treatment of bleeding episodes in hemophiliacs with inhibitors. Blood 1983;61:36-40.
6. Ingerslev J. Efficacy and safety of recombinant factor VIIa in the prophylaxis of bleeding in various surgical procedures in hemophilia patients with factor VIII and factor IX inhibitors. Semin Thromb Hemost 2000;26:425-432.
7. Scharrer I, Bray GL, Neutzling O. Incidence of inhibitors in hemophilia A patients-a review of recent studies of recombinant and plasma-derived factor VIII concentrates. Haemophilia 1999;5:145-154.
8. Ehrenforth S, Kreuz W, Scharrer l, et al. Incidence of development of factor VIII and factor IX inhibitors in haemophiliacs. Lancet 1992;339:594-598.
9. DiMichele DM. Immune tolerance: a synopsis of the international experience. Hemophilia 1998;4:568.
10. Lusher J, Ingersleve J, Roberts H, Hedner V. Clinical experience with recombinant factor VIIa. Blood Coagul Fibrinolysis 1998;9:119-128.
11. Key NS, Aledort LM, Beardsley D, et al. Home treatment of mild to moderate bleeding episodes using recombinant factor VIIa (NovoSeven) in haemophiliacs with inhibitors. Thromb Haemost 1998;80:912-918.
12. Negrier C, Goudemand J, Sultan Y, et al. Multicenter retrospective study on the utilization of FEIBA in France in patients with factor VIII and factor IX inhibitors. Thromb Haemost 1997;77:1113-1119.
13. Turecek PL, Varadi K, Keil B, et al. Factor VIII inhibitor-bypassing agents act by inducing thrombin generation and can be monitored by a thrombin generation assay. Pathophysiol Haemost Thromb 2003;33:16-22.
14. Ingerslev J, Christiansen K, Calatzis A, Holm M, Ebbesen LS. Management and monitoring of recombinant activated factor VII. Blood Coagul Fibrinolysis 2000;11(Suppl 1):25-29.
15. Rahimtoola ZO, van Baal SG. Two cases of acute carpal tunnel syndrome in classic haemophilia. Scand J Plast Reconstr Surg Hand Surg 2002;36:186-188.
16. Bruggers CS, Bleak S. Successful treatment of acquired factor VIII deficiency in a child using activated factor VII concentrates: case report and review of the literature. J Pediatr Hematol/Oncol 2003;25:578-580
17. Naranja RJ, Chan PS, High K, Esterhai JL, Heppenstall RB. Treatment of considerations in patients with compartment syndrome and an inherited bleeding disorder. Orthopedics 1997;20:706-711.
18. Key NS, Christie B, Henderson N, Nelsestuen GL. Possible synergy between recombinant factor VIIa and prothrombin complex concentrate in hemophilia therapy. Thromb Haemost 2002;88:60-65.
19. Allen GA, Monroe DM, Roberts HR, Hoffman M. The effect of factor X level on thrombin generation and the procoagulant effect of activated factor VII in a cell-based model of coagulation. Blood Coagul Fibrinolysis 2000;1(Suppl):3-7.
20. Tomokiyo K, Nakatomi Y, Araki T, et al. A novel therapeutic approach combining human plasma-derived factors VIIa and X for haemophiliacs with inhibitors: evidence of a higher thrombin generation rate in vitro and more sustained haemostatic activity in vivo than obtained with Factor VIIa alone. Vox Sang 2003;85:290-299.
21. Girolami A, Molaro G, De Marco L. Factor X survival and therapeutic factor X levels in the abnormal factor X (factor X Friuli) coagulation disorder. Acta Haematol 1974;52:223-231.